



CPT® Proprietary Laboratory Analyses (PLA) Codes: Long Descriptors

It is important to note that further CPT Editorial Panel (Panel) or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions may result in gaps in code number sequencing.

Most recent changes to the CPT® Proprietary Laboratory Analyses (PLA) Long Descriptor document

- Clarification that the duplicate PLA symbol and parenthetical note following the code descriptor of code 0202U will be published in CPT 2022.
- Addition of 2 PLA codes (0225U, 0226U) accepted by the CPT Editorial Panel.
- Deleted codes in this document appear with a ~~strikethrough~~.

Proprietary laboratory analyses (PLA) codes describe proprietary clinical laboratory analyses and can be either provided by a single (“sole-source”) laboratory or licensed or marketed to multiple providing laboratories (eg, cleared or approved by the Food and Drug Administration [FDA]).

This subsection includes advanced diagnostic laboratory tests (ADLTs) and clinical diagnostic laboratory tests (CDLTs), as defined under the Protecting Access to Medicare Act (PAMA) of 2014. These analyses may include a range of medical laboratory tests including, but not limited to, multianalyte assays with algorithmic analyses (MAAA) and genomic sequencing procedures (GSP). The descriptor nomenclature follows, where possible, existing code conventions (eg, MAAA, GSP).

Unless specifically noted, even though the Proprietary Laboratory Analyses section of the code set is located at the end of the Pathology and Laboratory section of the code set, a PLA code does not fulfill Category I code criteria. PLA codes are not required to fulfill the Category I criteria. The standards for inclusion in the PLA section are:

- The test must be commercially available in the United States for use on human specimens and
- The clinical laboratory or manufacturer that offers the test must request the code.

For similar laboratory analyses that fulfill Category I criteria, see codes listed in the numeric 80000 series.

When a PLA code is available to report a given proprietary laboratory service, that PLA code takes precedence. The service should not be reported with any other CPT code(s) and other CPT code(s) should not be used to report services that may be reported with that specific PLA code. These codes encompass all analytical services required for the analysis (eg, cell lysis, nucleic acid stabilization, extraction, digestion, amplification, hybridization and detection). For molecular analyses, additional procedures that are required prior to cell lysis (eg, microdissection [codes 88380 and 88381]) may be reported separately.

Codes in this subsection are released on a quarterly basis to expedite dissemination for reporting. PLA codes will be published electronically on the AMA CPT website (www.ama-assn.org/practice-management/cpt-pla-codes), distributed via CPT data files on a quarterly basis, and, at a minimum, made available in print annually in the CPT codebook. Go to www.ama-assn.org/sites/default/files/media-browser/public/physicians/cpt/cpt-pla-codes-long.pdf for the most current listing.



All codes that are included in this section are also included in Appendix O, with the procedure's proprietary name. In order to report a PLA code, the analysis performed must fulfill the code descriptor and must be the test represented by the proprietary name listed in Appendix O. In some instances, the descriptor language of PLA codes may be identical and the code may only be differentiated by the listed proprietary name in Appendix O. When more than one PLA has an identical descriptor, the codes will be denoted by the symbol "✕."

All PLA tests will have assigned codes in the PLA section of the code set. Any PLA coded test(s) that satisfies Category I criteria and has been accepted by the CPT Editorial Panel will be designated by the addition of the symbol "↑↓" to the existing PLA code and will remain in the PLA section of the code set.

If a proprietary test has already been accepted for a Category I code and a code has not been published, subsequent application for a PLA code will take precedence. The code will only be placed in the PLA section.

Proprietary Name and Clinical Laboratory and/or Manufacturer	Code	Long Code Descriptor	Released to AMA Website	Effective Date	Publication
Drug-drug, Drug-substance Identification and Interaction, Aegis Sciences Corporation	0006U	Detection of interacting medications, substances, supplements and foods, 120 or more analytes, definitive chromatography with mass spectrometry, urine, description and severity of each interaction identified, per date of service ▶(0006U has been deleted)◀	Deletion Released to AMA Website January 1, 2020	Deletion Effective April 1, 2020	Deletion Publication CPT® 2021
▶MYCODART-PCR™ Dual Amplification Real Time PCR Panel for 6 Candida species, RealTime Laboratories, Inc/MycoDART, Inc, RealTime Laboratories, Inc◀	0068U	Candida species panel (<i>C. albicans</i> , <i>C. glabrata</i> , <i>C. parapsilosis</i> , <i>C. kruseii</i> , <i>C. tropicalis</i> , and <i>C. auris</i>), amplified probe technique with qualitative report of the presence or absence of each species	April 1, 2020 Name Change Release to AMA Website April 1, 2020	July 1, 2020 Name Change Effective July 1, 2020	CPT® 2021
IBS^{chek}™, Commonwealth Diagnostics International, Inc	●0085U	Cytotoxic distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (ie, ELISA) ▶(0085U has been deleted)◀	April 1, 2019 Deletion Released to AMA Website October 1, 2019	July 1, 2019 Deletion Effective January 1, 2020	CPT® 2020 Deletion Publication CPT® 2021

First Trimester Screen+ FBS SM , Eurofins NTD, LLC, Eurofins NTD, LLC	0124U	Fetal congenital abnormalities, biochemical assays of 3 analytes (free beta-hCG, PAPP-A, AFP), time-resolved fluorescence immunoassay, maternal dried-blood spot, algorithm reported as risk scores for fetal trisomies 13/18 and 21	Deletion Released to AMA Website April 1, 2020	Deletion Effective July 1, 2020	Deletion Publication CPT® 2021
Maternal Fetal Screen+ T1 SM , Eurofins NTD, LLC, Eurofins NTD, LLC	0125U	Fetal congenital abnormalities and perinatal complications, biochemical assays of 5 analytes (free beta-hCG, PAPP-A, AFP, placental growth factor, and inhibin-A), time-resolved fluorescence immunoassay, maternal serum, algorithm reported as risk scores for fetal trisomies 13/18, 21, and preeclampsia	Deletion Released to AMA Website April 1, 2020	Deletion Effective July 1, 2020	Deletion Publication CPT® 2021
Maternal Fetal Screen+ T1 + Y Chromosome SM , Eurofins NTD, LLC, Eurofins NTD, LLC	0126U	Fetal congenital abnormalities and perinatal complications, biochemical assays of 5 analytes (free beta-hCG, PAPP-A, AFP, placental growth factor, and inhibin-A), time-resolved fluorescence immunoassay, includes qualitative assessment of Y chromosome in cell-free fetal DNA, maternal serum and plasma, predictive algorithm reported as risk scores for fetal trisomies 13/18, 21, and preeclampsia	Deletion Released to AMA Website April 1, 2020	Deletion Effective July 1, 2020	Deletion Publication CPT® 2021
Preeclampsia Screen+ T1 SM , Eurofins NTD, LLC, Eurofins NTD, LLC	0127U	Obstetrics (preeclampsia), biochemical assays of 3 analytes (PAPP-A, AFP, and placental growth factor), time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia	Deletion Released to AMA Website April 1, 2020	Deletion Effective July 1, 2020	Deletion Publication CPT® 2021
Preeclampsia Screen+ T1 + Y Chromosome SM , Eurofins NTD, LLC, Eurofins NTD, LLC	0128U	Obstetrics (preeclampsia), biochemical assays of 3 analytes (PAPP-A, AFP, and placental growth factor), time-resolved fluorescence immunoassay, includes qualitative assessment of Y chromosome in cell-free fetal DNA, maternal serum and plasma, predictive algorithm reported as a risk score for preeclampsia	Deletion Released to AMA Website April 1, 2020	Deletion Effective July 1, 2020	Deletion Publication CPT® 2021
NPDX ASD Energy Metabolism, Stemina Biomarker Discovery, Inc, Stemina Biomarker Discovery, Inc	●0139U	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 6 central carbon metabolites (ie, α-ketoglutarate, alanine, lactate, phenylalanine, pyruvate, and succinate), LC-MS/MS, plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD)	October 1, 2019	January 1, 2020	CPT® 2021



ePlex® BCID Fungal Pathogens Panel, GenMark Diagnostics, Inc, GenMark Diagnostics, Inc	●0140U	Infectious disease (fungi), fungal pathogen identification, DNA (15 fungal targets), blood culture, amplified probe technique, each target reported as detected or not detected	October 1, 2019	January 1, 2020	CPT® 2021
ePlex® BCID Gram-Positive Panel, GenMark Diagnostics, Inc, GenMark Diagnostics, Inc	●0141U	Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element detection, DNA (20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan Candida target), blood culture, amplified probe technique, each target reported as detected or not detected	October 1, 2019	January 1, 2020	CPT® 2021
ePlex® BCID Gram-Negative Panel, GenMark Diagnostics, Inc, GenMark Diagnostics, Inc	●0142U	Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, DNA (21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan Candida target), amplified probe technique, each target reported as detected or not detected	October 1, 2019	January 1, 2020	CPT® 2021
CareViewRx, Newstar Medical Laboratories, LLC, Newstar Medical Laboratories, LLC	✕●0143U	Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service ▶(For additional PLA code with identical clinical descriptor, see 0150U. See Appendix O to determine appropriate code assignment)◀	October 1, 2019	January 1, 2020	CPT® 2021
CareViewRx Plus, Newstar Medical Laboratories, LLC, Newstar Medical Laboratories, LLC	●0144U	Drug assay, definitive, 160 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	October 1, 2019	January 1, 2020	CPT® 2021



PainViewRx, Newstar Medical Laboratories, LLC, Newstar Medical Laboratories, LLC	●0145U	Drug assay, definitive, 65 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	October 1, 2019	January 1, 2020	CPT® 2021
PainViewRx Plus, Newstar Medical Laboratories, LLC, Newstar Medical Laboratories, LLC	●0146U	Drug assay, definitive, 80 or more drugs or metabolites, urine, by quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	October 1, 2019	January 1, 2020	CPT® 2021
RiskViewRx, Newstar Medical Laboratories, LLC, Newstar Medical Laboratories, LLC	●0147U	Drug assay, definitive, 85 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	October 1, 2019	January 1, 2020	CPT® 2021
RiskViewRx Plus, Newstar Medical Laboratories, LLC, Newstar Medical Laboratories, LLC	●0148U	Drug assay, definitive, 100 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	October 1, 2019	January 1, 2020	CPT® 2021
PsychViewRx, Newstar Medical Laboratories, LLC, Newstar Medical Laboratories, LLC	●0149U	Drug assay, definitive, 60 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	October 1, 2019	January 1, 2020	CPT® 2021
PsychViewRx Plus, Newstar Medical Laboratories, LLC, Newstar Medical Laboratories, LLC	✕●0150U	Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service ▶(For additional PLA code with identical clinical descriptor, see 0143U. See Appendix O to determine appropriate code assignment)◀	October 1, 2019	January 1, 2020	CPT® 2021

BioFire® FilmArray® Pneumonia Panel, BioFire® Diagnostics, BioFire® Diagnostics	●0151U	Infectious disease (bacterial or viral respiratory tract infection), pathogen specific nucleic acid (DNA or RNA), 33 targets, real-time semi-quantitative PCR, bronchoalveolar lavage, sputum, or endotracheal aspirate, detection of 33 organismal and antibiotic resistance genes with limited semi-quantitative results	October 1, 2019	January 1, 2020	CPT® 2021
Karius® Test, Karius Inc, Karius Inc	●0152U	Infectious disease (bacteria, fungi, parasites, and DNA viruses), DNA, PCR and next-generation sequencing, plasma, detection of >1,000 potential microbial organisms for significant positive pathogens	October 1, 2019	January 1, 2020	CPT® 2021
Insight TNBCtype™, Insight Molecular Labs	●0153U	Oncology (breast), mRNA, gene expression profiling by next-generation sequencing of 101 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a triple negative breast cancer clinical subtype(s) with information on immune cell involvement	October 1, 2019	January 1, 2020	CPT® 2021
therascreen® FGFR RGQ RT-PCR Kit, QIAGEN, QIAGEN GmbH	●▲0154U	<u>Oncology (urothelial cancer), RNA, analysis by real-time RT-PCR of the FGFR3 (fibroblast growth factor receptor 3) gene analysis (ie, p.R248C [c.742C>T], p.S249C [c.746C>G], p.G370C [c.1108G>T], p.Y373C [c.1118A>G], FGFR3-TACC3v1, and FGFR3-TACC3v3), utilizing formalin-fixed paraffin-embedded urothelial cancer tumor tissue, reported as FGFR gene alteration status</u>	October 1, 2019 Revision Posted to AMA Website January 1, 2020	January 1, 2020 Revision Effective April 1, 2020	CPT® 2021 Revision Publication CPT® 2021
therascreen® PIK3CA RGQ PCR Kit, QIAGEN, QIAGEN GmbH	●▲0155U	<u>Oncology (breast cancer), DNA, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) (eg, breast cancer) gene analysis (ie, p.C420R, p.E542K, p.E545A, p.E545D [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y), utilizing formalin-fixed paraffin-embedded breast tumor tissue, reported as PIK3CA gene mutation status</u>	October 1, 2019 Revision Posted to AMA Website January 1, 2020	January 1, 2020 Revision Effective April 1, 2020	CPT® 2021 Revision Publication CPT® 2021
SMASH™, New York Genome Center, Marvel Genomics™	●0156U	Copy number (eg, intellectual disability, dysmorphology), sequence analysis	October 1, 2019	January 1, 2020	CPT® 2021
CustomNext + RNA: APC, Ambry Genetics®, Ambry Genetics®	+●0157U	APC (APC regulator of WNT signaling pathway) (eg, familial adenomatous polyposis [FAP]) mRNA sequence analysis	October 1, 2019	January 1, 2020	CPT® 2021

		(List separately in addition to code for primary procedure) ▶(Use 0157U in conjunction with 81201)◀			
CustomNext + RNA: <i>MLH1</i> , Ambry Genetics®, Ambry Genetics®	+●0158U	<i>MLH1 (mutL homolog 1)</i> (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) ▶(Use 0158U in conjunction with 81292)◀	October 1, 2019	January 1, 2020	CPT® 2021
CustomNext + RNA: <i>MSH2</i> , Ambry Genetics®, Ambry Genetics®	+●0159U	<i>MSH2 (mutS homolog 2)</i> (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) ▶(Use 0159U in conjunction with 81295)◀	October 1, 2019	January 1, 2020	CPT® 2021
CustomNext + RNA: <i>MSH6</i> , Ambry Genetics®, Ambry Genetics®	+●0160U	<i>MSH6 (mutS homolog 6)</i> (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) ▶(Use 0160U in conjunction with 81298)◀	October 1, 2019	January 1, 2020	CPT® 2021
CustomNext + RNA: <i>PMS2</i> , Ambry Genetics®, Ambry Genetics®	+●0161U	<i>PMS2 (PMS1 homolog 2, mismatch repair system component)</i> (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) ▶(Use 0161U in conjunction with 81317)◀	October 1, 2019	January 1, 2020	CPT® 2021
CustomNext + RNA: Lynch (<i>MLH1</i> , <i>MSH2</i> , <i>MSH6</i> , <i>PMS2</i>), Ambry Genetics®, Ambry Genetics®	+●0162U	Hereditary colon cancer (Lynch syndrome), targeted mRNA sequence analysis panel (<i>MLH1</i> , <i>MSH2</i> , <i>MSH6</i> , <i>PMS2</i>) (List separately in addition to code for primary procedure) ▶(Use 0162U in conjunction with 81292, 81295, 81298, 81317, 81435)◀	October 1, 2019	January 1, 2020	CPT® 2021
BeScreened™-CRC, Beacon Biomedical Inc, Beacon Biomedical Inc	●0163U	Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins (teratocarcinoma derived growth factor-1 [TDGF-1, Cripto-1], carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]), with demographic data (age, gender, CRC-screening compliance) using a proprietary algorithm and reported as likelihood of CRC or advanced adenomas	January 1, 2020	April 1, 2020	CPT® 2021

ibs-smart™, Gemelli Biotech, Gemelli Biotech	●0164U	Gastroenterology (irritable bowel syndrome [IBS]), immunoassay for anti-CdtB and anti-vinculin antibodies, utilizing plasma, algorithm for elevated or not elevated qualitative results	January 1, 2020	April 1, 2020	CPT® 2021
VeriMAP™ Peanut Dx – Bead-based Epitope Assay, AllerGenis™ Clinical Laboratory, AllerGenis™ LLC	●▲0165U	Peanut allergen-specific IgE and quantitative assessment of 64 multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, individual epitope results and interpretation probability of peanut allergy	January 1, 2020 Revision Posted to AMA Website April 1, 2020	April 1, 2020 Revision Effective July 1, 2020	CPT® 2021 Revision Publication CPT® 2021
LiverFASt™, Fibronostics, Fibronostics	●0166U	Liver disease, 10 biochemical assays (α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation	January 1, 2020	April 1, 2020	CPT® 2021
ADEXUSDx hCG Test, NOWDiagnostics, NOWDiagnostics	●0167U	Gonadotropin, chorionic (hCG), immunoassay with direct optical observation, blood	January 1, 2020	April 1, 2020	CPT® 2021
Vanadis® NIPT, PerkinElmer, Inc, PerkinElmer Genomics	●0168U	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma without fetal fraction cutoff, algorithm reported as a risk score for each trisomy	January 1, 2020	April 1, 2020	CPT® 2021
NT (NUDT15 and TPMT) genotyping panel, RPRD Diagnostics	●0169U	NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug metabolism) gene analysis, common variants	January 1, 2020	April 1, 2020	CPT® 2021
Clarifi™, Quadrant Biosciences, Inc, Quadrant Biosciences, Inc	●0170U	Neurology (autism spectrum disorder [ASD]), RNA, next-generation sequencing, saliva, algorithmic analysis, and results reported as predictive probability of ASD diagnosis	January 1, 2020	April 1, 2020	CPT® 2021

MyMRD® NGS Panel, Laboratory for Personalized Molecular Medicine, Laboratory for Personalized Molecular Medicine	●0171U	Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/absence	January 1, 2020	April 1, 2020	CPT® 2021
myChoice® CDx, Myriad Genetics Laboratories, Inc, Myriad Genetics Laboratories, Inc	●0172U	Oncology (solid tumor as indicated by the label), somatic mutation analysis of <i>BRCA1</i> (<i>BRCA1</i> , <i>DNA repair associated</i>), <i>BRCA2</i> (<i>BRCA2</i> , <i>DNA repair associated</i>) and analysis of homologous recombination deficiency pathways, DNA, formalin-fixed paraffin-embedded tissue, algorithm quantifying tumor genomic instability score	April 1, 2020	July 1, 2020	CPT® 2021
Psych HealthPGx Panel, RPRD Diagnostics, RPRD Diagnostics	●0173U	Psychiatry (ie, depression, anxiety), genomic analysis panel, includes variant analysis of 14 genes	April 1, 2020	July 1, 2020	CPT® 2021
LC-MS/MS Targeted Proteomic Assay, OncoOmicDx Laboratory, LDT	●0174U	Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin-embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents	April 1, 2020	July 1, 2020	CPT® 2021
Genomind® Professional PGx Express™ CORE, Genomind, Inc, Genomind, Inc	●0175U	Psychiatry (eg, depression, anxiety), genomic analysis panel, variant analysis of 15 genes	April 1, 2020	July 1, 2020	CPT® 2021
IBS <i>chek</i> ®, Commonwealth Diagnostics International, Inc, Commonwealth Diagnostics International, Inc	●0176U	Cytolethal distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (ie, ELISA)	April 1, 2020	July 1, 2020	CPT® 2021
therascreen® <i>PIK3CA</i> RGQ PCR Kit, QIAGEN, QIAGEN GmbH	●0177U	Oncology (breast cancer), DNA, <i>PIK3CA</i> (<i>phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha</i>) gene analysis of 11 gene variants utilizing plasma, reported as <i>PIK3CA</i> gene mutation status	April 1, 2020	July 1, 2020	CPT® 2021

VeriMAP™ Peanut Sensitivity – Bead Based Epitope Assay, AllerGenis™ Clinical Laboratory, AllerGenis™ LLC	●0178U	Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, report of minimum eliciting exposure for a clinical reaction	April 1, 2020	July 1, 2020	CPT® 2021
Resolution ctDx Lung™, Resolution Bioscience, Resolution Bioscience, Inc	●0179U	Oncology (non-small cell lung cancer), cell-free DNA, targeted sequence analysis of 23 genes (single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, copy number variations), with report of significant mutation(s)	April 1, 2020	July 1, 2020	CPT® 2021
Navigator ABO Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0180U	Red cell antigen (ABO blood group) genotyping (ABO), gene analysis Sanger/chain termination/conventional sequencing, <i>ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase)</i> gene, including subtyping, 7 exons	April 1, 2020	July 1, 2020	CPT® 2021
Navigator CO Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0181U	Red cell antigen (Colton blood group) genotyping (CO), gene analysis, <i>AQP1 (aquaporin 1 [Colton blood group])</i> exon 1	April 1, 2020	July 1, 2020	CPT® 2021
Navigator CROM Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0182U	Red cell antigen (Cromer blood group) genotyping (CROM), gene analysis, <i>CD55 (CD55 molecule [Cromer blood group])</i> exons 1-10	April 1, 2020	July 1, 2020	CPT® 2021
Navigator DI Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0183U	Red cell antigen (Diego blood group) genotyping (DI), gene analysis, <i>SLC4A1 (solute carrier family 4 member 1 [Diego blood group])</i> exon 19	April 1, 2020	July 1, 2020	CPT® 2021
Navigator DO Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0184U	Red cell antigen (Dombrock blood group) genotyping (DO), gene analysis, <i>ART4 (ADP-ribosyltransferase 4 [Dombrock blood group])</i> exon 2	April 1, 2020	July 1, 2020	CPT® 2021
Navigator FUT1 Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0185U	Red cell antigen (H blood group) genotyping (FUT1), gene analysis, <i>FUT1 (fucosyltransferase 1 [H blood group])</i> exon 4	April 1, 2020	July 1, 2020	CPT® 2021

Navigator FUT2 Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0186U	Red cell antigen (H blood group) genotyping (FUT2), gene analysis, <i>FUT2</i> (<i>fucosyltransferase 2</i>) exon 2	April 1, 2020	July 1, 2020	CPT® 2021
Navigator FY Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0187U	Red cell antigen (Duffy blood group) genotyping (FY), gene analysis, <i>ACKR1</i> (<i>atypical chemokine receptor 1 [Duffy blood group]</i>) exons 1-2	April 1, 2020	July 1, 2020	CPT® 2021
Navigator GE Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0188U	Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis, <i>GYPC</i> (<i>glycophorin C [Gerbich blood group]</i>) exons 1-4	April 1, 2020	July 1, 2020	CPT® 2021
Navigator GYPA Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0189U	Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, <i>GYPA</i> (<i>glycophorin A [MNS blood group]</i>) introns 1, 5, exon 2	April 1, 2020	July 1, 2020	CPT® 2021
Navigator GYPB Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0190U	Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, <i>GYPB</i> (<i>glycophorin B [MNS blood group]</i>) introns 1, 5, pseudoexon 3	April 1, 2020	July 1, 2020	CPT® 2021
Navigator IN Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0191U	Red cell antigen (Indian blood group) genotyping (IN), gene analysis, <i>CD44</i> (<i>CD44 molecule [Indian blood group]</i>) exons 2, 3, 6	April 1, 2020	July 1, 2020	CPT® 2021
Navigator JK Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0192U	Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, <i>SLC14A1</i> (<i>solute carrier family 14 member 1 [Kidd blood group]</i>) gene promoter, exon 9	April 1, 2020	July 1, 2020	CPT® 2021
Navigator JR Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0193U	Red cell antigen (JR blood group) genotyping (JR), gene analysis, <i>ABCG2</i> (<i>ATP binding cassette subfamily G member 2 [Junior blood group]</i>) exons 2-26	April 1, 2020	July 1, 2020	CPT® 2021

Navigator KEL Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0194U	Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, <i>KEL</i> (<i>Kell metallo-endopeptidase [Kell blood group]</i>) exon 8	April 1, 2020	July 1, 2020	CPT® 2021
Navigator <i>KLF1</i> Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0195U	<i>KLF1</i> (<i>Kruppel-like factor 1</i>), targeted sequencing (ie, exon 13)	April 1, 2020	July 1, 2020	CPT® 2021
Navigator LU Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0196U	Red cell antigen (Lutheran blood group) genotyping (LU), gene analysis, <i>BCAM</i> (<i>basal cell adhesion molecule [Lutheran blood group]</i>) exon 3	April 1, 2020	July 1, 2020	CPT® 2021
Navigator LW Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0197U	Red cell antigen (Landsteiner-Wiener blood group) genotyping (LW), gene analysis, <i>ICAM4</i> (<i>intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]</i>) exon 1	April 1, 2020	July 1, 2020	CPT® 2021
Navigator RHD/CE Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0198U	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, <i>RHD</i> (<i>Rh blood group D antigen</i>) exons 1-10 and <i>RHCE</i> (<i>Rh blood group CcEe antigens</i>) exon 5	April 1, 2020	July 1, 2020	CPT® 2021
Navigator SC Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0199U	Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, <i>ERMAP</i> (<i>erythroblast membrane associated protein [Scianna blood group]</i>) exons 4, 12	April 1, 2020	July 1, 2020	CPT® 2021
Navigator XK Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0200U	Red cell antigen (Kx blood group) genotyping (XK), gene analysis, <i>XK</i> (<i>X-linked Kx blood group</i>) exons 1-3	April 1, 2020	July 1, 2020	CPT® 2021
Navigator YT Sequencing, Grifols Immunohematology Center, Grifols Immunohematology Center	●0201U	Red cell antigen (Yt blood group) genotyping (YT), gene analysis, <i>ACHE</i> (<i>acetylcholinesterase [Cartwright blood group]</i>) exon 2	April 1, 2020	July 1, 2020	CPT® 2021

<p>BioFire® Respiratory Panel 2.1 (RP2.1), BioFire® Diagnostics, BioFire® Diagnostics, LLC</p>	<p>✕●0202U</p>	<p>Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected</p> <p>▶(For additional PLA code with identical clinical descriptor, see 0223U. See Appendix O or the most current listing on the AMA CPT website to determine appropriate code assignment)◀</p>	<p>May 20, 2020</p>	<p>May 20, 2020</p>	<p>CPT® 2021</p> <p style="text-align: center;">Duplicate PLA Symbol and Parenthetical Note Added to Publication CPT® 2022</p>
<p>PredictSURE IBD™ Test, KSL Diagnostics, PredictImmune Ltd</p>	<p>●0203U</p>	<p>Autoimmune (inflammatory bowel disease), mRNA, gene expression profiling by quantitative RT-PCR, 17 genes (15 target and 2 reference genes), whole blood, reported as a continuous risk score and classification of inflammatory bowel disease aggressiveness</p>	<p>July 1, 2020</p>	<p>October 1, 2020</p>	<p>CPT® 2021</p>
<p>Afirma Xpression Atlas, Veracyte, Inc, Veracyte, Inc</p>	<p>●0204U</p>	<p>Oncology (thyroid), mRNA, gene expression analysis of 593 genes (including <i>BRAF</i>, <i>RAS</i>, <i>RET</i>, <i>PAX8</i>, and <i>NTRK</i>) for sequence variants and rearrangements, utilizing fine needle aspirate, reported as detected or not detected</p>	<p>July 1, 2020</p>	<p>October 1, 2020</p>	<p>CPT® 2021</p>
<p>Vita Risk®, Arctic Medical Laboratories, Arctic Medical Laboratories</p>	<p>●0205U</p>	<p>Ophthalmology (age-related macular degeneration), analysis of 3 gene variants (2 <i>CFH</i> gene, 1 <i>ARMS2</i> gene), using PCR and MALDI-TOF, buccal swab, reported as positive or negative for neovascular age-related macular-degeneration risk associated with zinc supplements</p>	<p>July 1, 2020</p>	<p>October 1, 2020</p>	<p>CPT® 2021</p>
<p>DISCERN™, NeuroDiagnostics, NeuroDiagnostics</p>	<p>●0206U</p> <p>+</p> <p>●0207U</p>	<p>Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease</p> <p>quantitative imaging of phosphorylated <i>ERK1</i> and <i>ERK2</i> in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to code for primary procedure)</p>	<p>July 1, 2020</p>	<p>October 1, 2020</p>	<p>CPT® 2021</p>

		▶(Use 0207U in conjunction with 0206U)◀			
Afirma Medullary Thyroid Carcinoma (MTC) Classifier, Veracyte, Inc, Veracyte, Inc	●0208U	Oncology (medullary thyroid carcinoma), mRNA, gene expression analysis of 108 genes, utilizing fine needle aspirate, algorithm reported as positive or negative for medullary thyroid carcinoma	July 1, 2020	October 1, 2020	CPT® 2021
CNGnome™, PerkinElmer Genomics, PerkinElmer Genomics	●0209U	Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities	July 1, 2020	October 1, 2020	CPT® 2021
BioPlex 2200 RPR Assay - Quantitative, Bio-Rad Laboratories, Bio-Rad Laboratories	●0210U	Syphilis test, non-treponemal antibody, immunoassay, quantitative (RPR)	July 1, 2020	October 1, 2020	CPT® 2021
MI Cancer Seek™ - NGS Analysis, Caris MPI d/b/a Caris Life Sciences, Caris MPI d/b/a Caris Life Sciences	●0211U	Oncology (pan-tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association	July 1, 2020	October 1, 2020	CPT® 2021
Genomic Unity® Whole Genome Analysis - Proband, Variantyx Inc, Variantyx Inc	●0212U	Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband ▶(Do not report 0212U in conjunction with 81425)◀	July 1, 2020	October 1, 2020	CPT® 2021
Genomic Unity® Whole Genome Analysis - Comparator, Variantyx Inc, Variantyx Inc	●0213U	Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of	July 1, 2020	October 1, 2020	CPT® 2021

		genetic variants, each comparator genome (eg, parent, sibling) ▶(Do not report 0213U in conjunction with 81426)◀			
Genomic Unity® Exome Plus Analysis - Proband, Variantyx Inc, Variantyx Inc	●0214U	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband ▶(Do not report 0214U in conjunction with 81415)◀	July 1, 2020	October 1, 2020	CPT® 2021
Genomic Unity® Exome Plus Analysis - Comparator, Variantyx Inc, Variantyx Inc	●0215U	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator exome (eg, parent, sibling) ▶(Do not report 0215U in conjunction with 81416)◀	July 1, 2020	October 1, 2020	CPT® 2021
Genomic Unity® Ataxia Repeat Expansion and Sequence Analysis, Variantyx Inc, Variantyx Inc	●0216U	Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants	July 1, 2020	October 1, 2020	CPT® 2021
Genomic Unity® Comprehensive Ataxia Repeat Expansion and Sequence Analysis, Variantyx Inc, Variantyx Inc	●0217U	Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants	July 1, 2020	October 1, 2020	CPT® 2021
Genomic Unity® DMD Analysis, Variantyx Inc, Variantyx Inc	●0218U	Neurology (muscular dystrophy), <i>DMD</i> gene sequence analysis, including small sequence changes, deletions, duplications, and variants in non-uniquely mappable regions, blood or	July 1, 2020	October 1, 2020	CPT® 2021

		saliva, identification and characterization of genetic variants			
Sentosa® SQ HIV-1 Genotyping Assay, Vela Diagnostics USA, Inc, Vela Operations Singapore Pte Ltd	●0219U	Infectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (ie, protease [PR], reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility	July 1, 2020	October 1, 2020	CPT® 2021
PreciseDx™ Breast Cancer Test, PreciseDx, PreciseDx	●0220U	Oncology (breast cancer), image analysis with artificial intelligence assessment of 12 histologic and immunohistochemical features, reported as a recurrence score	July 1, 2020	October 1, 2020	CPT® 2021
Navigator ABO Blood Group NGS, Grifols Immunoematology Center, Grifols Immunoematology Center	●0221U	Red cell antigen (ABO blood group) genotyping (ABO), gene analysis, next-generation sequencing, <i>ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene</i>	July 1, 2020	October 1, 2020	CPT® 2021
Navigator Rh Blood Group NGS, Grifols Immunoematology Center, Grifols Immunoematology Center	●0222U	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis, next-generation sequencing, RH proximal promoter, exons 1-10, portions of introns 2-3	July 1, 2020	October 1, 2020	CPT® 2021
QIAstat-Dx Respiratory SARS CoV-2 Panel, QIAGEN Sciences, QIAGEN GmbH	✕●0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected ▶(For additional PLA code with identical clinical descriptor, see 0202U. See Appendix O or the most current listing on the AMA CPT website to determine appropriate code assignment)◀	June 25, 2020	June 25, 2020	CPT® 2022
COVID-19 Antibody Test, Mt Sinai, Mount Sinai Laboratory	●0224U	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed ▶(Do not report 0224U in conjunction with 86769)◀	June 25, 2020	June 25, 2020	CPT® 2022



ePlex [®] Respiratory Pathogen Panel 2, GenMark Dx, GenMark Diagnostics, Inc	●0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected	August 10, 2020	August 10, 2020	CPT [®] 2022
Tru-Immune [™] , Ethos Laboratories, GenScript [®] USA Inc	●0226U	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum	August 10, 2020	August 10, 2020	CPT [®] 2022